HOME >> MEDICINE >> NEWS
Studying the fate of drugs in wastewater

Researchers at the National Institute of Standards and Technology (NIST) have published an interesting study that sheds light on the fate of a familiar pharmaceutical as it enters the waste stream. In work initially described last year, NIST chemists investigated probable chemical reactions involving acetaminophen when the drug is subjected to typical wastewater processing. Acetaminophen is the most widely used pain reliever in the United States, and a study of 139 streams by the U.S. Geological Survey found that it was one of the most frequently detected man-made chemicals.

The scientists found that the drug readily reacts in chlorine disinfection to form at least 11 new products, at least two of which are known to be toxic. The results, according to lead author Mary Bedner, demonstrate that environmental scientists need to be concerned about downstream reaction products as well as the original waste materials. "The issue is what you should be looking for in the environment," she says. "When you are looking for the effects of pharmaceuticals in the environment, you need to ask what they're going to turn into."


'"/>

Contact: Michael Baum
michael.baum@nist.gov
301-975-2763
National Institute of Standards and Technology (NIST)
23-Dec-2005


Page: 1

Related medicine news :

1. Studying brain activity could aid diagnosis of social phobia
2. UIC researchers to develop new drugs to fight bioterrorism
3. Statin drugs may delay progressive artery damage in children
4. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
5. Experts call for urgent research into anti-epileptic drugs given to children
6. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells
7. Antipsychotic drugs increase risk of death in older people with dementia
8. Antipsychotic drugs increase risk of death in older people with dementia
9. Gene variations point to why lung cancer drugs work better in Japanese vs. US patients
10. Panel offers guidelines on skin reactions to new class of cancer drugs
11. Blood-thinning drugs need closer monitoring

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Studying the fate drugs wastewater

(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
(Date:12/17/2014)... HOLBROOK, N.Y. , Dec. 17, 2014 /PRNewswire/ ... that The Depository Trust Company (DTC) has made ... the Deposit Chill on the Company,s stock effective ... of Northstar,s common stock for depository and book ... and the Company is now once again fully ...
(Date:12/17/2014)... MILAN , December 17, 2014 ... becoming nothing less than a hub of information concerning the ... A further addition to the recently launched ... world and has now been enriched by a new chapter ... A richly detailed and panoramic hub on ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014  RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced completion of enrollment in its ... from the 3-month observations confirmed the 1-month findings ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
Cached News: